# Treatment options for Fabry disease
Treatment of Fabry disease focuses on supplementing or replacing the missing enzyme alpha-galactosidase A, reducing harmful substances in the body, and preventing or slowing complications affecting the heart, kidneys, and nervous system. In the coming years, we will see new mechanisms of action emerging alongside classical enzyme replacement.
Enzyme replacement therapy (ERT)
ProveniIncluded in official guidelines, or approved by EMA or FDA
In enzyme replacement therapy, the patient receives the missing enzyme alpha-galactosidase A administered via infusion. This enzyme is produced in the laboratory and can break down the accumulation of globotriaosylceramide (Gb3) in cells. The enzyme is usually delivered directly into the bloodstream through an infusion, after which it is transported to various organs.
Enzyme replacement therapy has been the standard treatment for more than twenty years and is included in all international guidelines. Studies show that starting early can slow the course of the disease, especially in men and in patients without severe kidney or heart damage.
Known side effects are reactions during or after the infusion (redness, fever, itching, shortness of breath), usually becoming less frequent as treatment continues. Some patients develop antibodies against the enzyme, which can affect its effectiveness.
Chaperone therapy (Pharmacological Chaperones)
ProveniIncluded in official guidelines, or approved by EMA or FDA
Chaperone therapy uses small molecules that stabilize and repair the body's own enzyme (when present, but malformed). These molecules bind to the damaged enzyme, help it fold into the correct shape, and enable it to function better.
Migalastat is the most commonly used chaperone and is approved for use in patients with specific GLA gene variants that are 'amenable' (suitable) for this mechanism. It is administered orally (in tablets), which offers advantages for patients who find infusions difficult to tolerate or who prefer to be treated at home.
Chaperone therapy works only for specific genetic variants. Your own GLA variant determines whether this approach is suitable for you. Known side effects are generally mild: headache, nausea, and diarrhea occur in a small proportion of users. Because the medication is processed through the liver, liver function is monitored regularly.
Substrate reduction therapy (SRT)
ProveniIncluded in official guidelines, or approved by EMA or FDA
In substrate reduction, the production of the harmful substance (Gb3) itself is slowed down, rather than breaking down this substance. This causes the substance to accumulate more slowly in cells. This works at a completely different level than enzyme replacement.
Eliglustat and Lucerastat are medications in this class. Eliglustat has been incorporated into guidelines as a treatment option for certain patients; Lucerastat is being further investigated in clinical trials and is already being used in some countries.
These medications are administered orally. Lucerastat can be used in patients with severely reduced kidney function, which offers an advantage for a group that is difficult to treat with infusions. Side effects are comparable to chaperone therapy: gastrointestinal disorders, headache, and in studies also effects on muscle strength (with long-term use under close monitoring).
Antiarrhythmic and cardiological support
ProveniIncluded in official guidelines, or approved by EMA or FDA
Many patients with Fabry disease develop heart rhythm disturbances and heart enlargement. Medications such as beta-blockers, ACE inhibitors, angiotensin II receptor blockers, and in some cases antiarrhythmic agents help prevent heart failure and maintain a stable rhythm.
These medications are not specific to Fabry disease, but are essential to prevent serious cardiac complications. They are prescribed and monitored by cardiologists, as Fabry patients sometimes present with atypical cardiac manifestations that require careful diagnosis and monitoring.
Side effects depend on the specific medication. Regular ECG and echocardiography are recommended to monitor effectiveness.
Kidney inflammation and kidney function
ProveniIncluded in official guidelines, or approved by EMA or FDA
Protection of the kidneys is achieved through ACE inhibitors or angiotensin II receptor blockers, which reduce protein excretion and prevent further damage. In severe kidney failure, dialysis may be necessary.
Some studies show that early kidney protection combined with enzyme replacement works better than either one alone.
Pain management
ProveniIncluded in official guidelines, or approved by EMA or FDA
Acropesthesia (burning foot and hand pain) is a common symptom. Regular pain relievers, local treatment and sometimes nerve-affecting medications (pregabalin, gabapentin) help. For severe pain, stronger medications may be considered.
Research into new mechanisms of action (including research into growth factors and immune modulation) is ongoing, but has not yet been included in routine care.
Gene therapy
ResearchediPositive results in clinical studies, not yet standard treatment
Gene therapy aims to directly repair or replace the defective GLA gene in body cells, so that the body can produce the enzyme itself. This is still in the research and early development phase and is not routinely available.
The first clinical trials show cautiously hopeful initial signals, but many questions about sustainability, safety and long-term effects remain open.
Agents under investigation targeting underlying processes
ExperimentaliOngoing in study setting, outcome still unknown
Studies running in 2026 are focusing on new points of intervention: modulation of A4GALT protein (involved in the accumulation of harmful substances), improvement of cellular autophagy (natural breakdown in cells) and neuroprotective agents. These are not yet available for routine treatment.
Studies on improved forms of the chaperone concept and combinations of substances are also underway, with the aim of further improving efficacy and effectiveness.
Supportive care
ProveniIncluded in official guidelines, or approved by EMA or FDA
In addition to medication, patients receive guidance from multiple specialists: cardiologist (heart), nephrologist (kidneys), neurologist (nervous system), otolaryngologist (hearing and balance problems) and psychologist (coping with chronic illness). Diet advice and adapted physical activity also play a role.
Regular examination of heart, kidney and nerve function helps detect complications early.
---
_This information never replaces a doctor's judgment. Always discuss your situation with your own healthcare provider._